NCT05866744

Brief Summary

The effects of a time-restricted hypocaloric Mediterranean type diet compared to a conventional hypocaloric Mediterranean type diet on blood glucose metabolism and liver steatosis in people with non-alcoholic fatty liver disease will be investigated.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
59

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2023

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 30, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

May 8, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

May 19, 2023

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 15, 2024

Completed
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2024

Completed
Last Updated

October 30, 2024

Status Verified

October 1, 2024

Enrollment Period

1.2 years

First QC Date

March 30, 2023

Last Update Submit

October 29, 2024

Conditions

Keywords

Time-Restricted FeedingMediterranean Diet

Outcome Measures

Primary Outcomes (1)

  • Change in blood glucose concentrations

    Clinically significant change in blood glucose concentrations (mg/dL)

    12 weeks

Secondary Outcomes (5)

  • Change in body weight

    12 weeks

  • Change in blood insulin concentrations

    12 weeks

  • Change in Controlled Attenuation Parameter (CAP)

    12 weeks

  • Change in blood lipids levels

    12 weeks

  • Change in Chronic Liver Disease Questionnaire (CLDQ)

    12 weeks

Study Arms (3)

Early Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet

EXPERIMENTAL

Early 14:10 time-restricted feeding plus hypocaloric Mediterranean diet

Other: Early Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet

Late Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet

EXPERIMENTAL

Late 14:10 time-restricted feeding plus hypocaloric Mediterranean diet

Other: Late Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet

Hypocaloric Mediterranean Diet Without Time Restriction In Feeding

ACTIVE COMPARATOR

Hypocaloric Mediterranean diet without time restriction in feeding

Other: Hypocaloric Mediterranean Diet Without Time Restriction In Feeding

Interventions

18 patients with NAFLD will be asked to follow an early 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 08:00-18:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks

Early Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet

18 patients with NAFLD will be asked to follow a late 14:10 (14 hours fasting and 10 hours feeding) time-restricted (eating between 12:00-22:00) and individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) for 12 weeks

Late Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet

18 patients with NAFLD will be asked to follow an individualized Mediterranean diet plan with caloric restriction (energy deficit of 500 kcal/day) without time restriction in feeding (eating throughout the day) for 12 weeks

Hypocaloric Mediterranean Diet Without Time Restriction In Feeding

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Body Mass Index \>25 kg/m2
  • Liver steatosis with Magnetic Resonance Elastography (MRE)

You may not qualify if:

  • Other chronic liver diseases
  • Alcohol consumption \>20 g/day (female) and \>30 g/day (male)
  • Medications that cause liver disease or secondary NAFLD (e.g. tamoxifen, corticosteroids, Methotrexate, tetracycline, estrogens, valproic acid)
  • Changes in body weight ± 3 % in the last 3 months
  • Patients following a hypocaloric diet program and/or time-restricted feeding and/or other intermittent fasting protocols
  • Unstable glucose-lowering medications in the last 6 months
  • Body weight lowering medications and/or history of bariatric surgery
  • Statins and/ or other fat-reducing medications if not taken in steady dosage for at least 3 months
  • Uncontrolled type 2 diabetes mellitus defined as HbA1c value \> 9.0% or insulin depending type 1 and 2 diabetes mellitus
  • Pregnancy
  • Lactation
  • Immunologic or inflammatory diseases
  • Depression and other psychiatric diseases
  • Patients working in shifts
  • Cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Laiko General Hospital of Athens

Athens, Attica, 11527, Greece

Location

Agricultural University of Athens

Athens, Attica, 11855, Greece

Location

Related Publications (1)

  • Tsitsou S, Bali T, Adamantou M, Saridaki A, Poulia KA, Karagiannakis DS, Papakonstantinou E, Cholongitas E. Effects of a 12-Week Mediterranean-Type Time-Restricted Feeding Protocol in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Controlled Trial-The 'CHRONO-NAFLD Project'. Aliment Pharmacol Ther. 2025 Apr;61(8):1290-1309. doi: 10.1111/apt.70044. Epub 2025 Feb 28.

MeSH Terms

Conditions

Non-alcoholic Fatty Liver DiseaseIntermittent Fasting

Condition Hierarchy (Ancestors)

Fatty LiverLiver DiseasesDigestive System DiseasesFastingFeeding BehaviorBehavior

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

March 30, 2023

First Posted

May 19, 2023

Study Start

May 8, 2023

Primary Completion

July 15, 2024

Study Completion

July 30, 2024

Last Updated

October 30, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations